Leveraging Novel Treatment Options for Small-Cell Lung Cancer in the Second Line to Optimize Community-Based Care
Post-Test/Evaluation

Questions marked with a * are required
26%
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Are you a Physician? 
A 74-year-old patient with SCLC shows signs of progression after four cycles of first line carboplatin plus etoposide and atezolizumab followed by four cycles of maintenance atezolizumab. He is started on lurbinectedin, which of the following adverse events may be a risk?
In the phase 2 trial evaluating talazoparib plus temozolomide for extensive-stage small cell lung cancer, which significant clinical benefit was reported?
A 68-year-old patient with a history of smoking presents with right-sided rib pain. PET/CT shows hypermetabolic R hilar mass in RUL measuring up to 4.9 cm; evidence of regional mediastinal lymphadenopathy and metastatic spread to R pleura without extrathoracic spread. Biopsy of right upper lung shows pathology consistent with SCLC. After four cycles of first line carboplatin plus etoposide and durvalumab followed by four cycles of maintenance durvalumab the patient shows extrathoracic progression of disease. Which of the following is the most appropriate next step in the management of this patient?
Powered by QuestionPro